search
Kodiak Sciences
Trends
- 1Kodiak Sciences Soars 150% After Drug Trial Success▼Kodiak Sciences Up 150% At Opening Bell After Drugs Pass Key Trial
Kodiak Sciences shares jumped roughly 150% at the opening bell after the biotech's drug passed a key clinical trial. The strong trial results triggered a sharp rally in the stock, making the eye-disease drug developer one of the day's biggest gainers and drawing investor attention to its pipeline prospects.
- 2Kodiak Sciences Says Its Eye Drug Matches Regeneron's Medicine▼Kodiak Sciences Says Eye Drug on Par with Regeneron's Medicine
Kodiak Sciences announced that its experimental eye drug performs on par with Regeneron's established treatment, according to a Benzinga report. The claim, if supported by trial data, would position the biotech as a credible challenger in the competitive market for retinal disease therapies, where Regeneron's medicine has long been a dominant option.
- 3Kodiak Sciences' Eye Treatment Succeeds in Phase III Trial▼Phase III Success Pushes Kodiak’s Eye Treatment Towards Approval
Kodiak Sciences reports that its experimental eye treatment has succeeded in a Phase III clinical trial, moving the therapy a step closer to regulatory approval. The positive late-stage results put the biotech company on track to file for authorization, offering a potential new option for patients with retinal disease. Details on the specific condition treated and the data were not provided.